AEAmin Motamed Ektesabi

Amin Motamed Ektesabi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amin Motamed Ektesabi has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Implementation of in-house Xpert MTB/RIF Ultra testing reduces diagnostic turnaround time and modeled airborne isolation costs

    by Amin Ektesabi, Jennifer Tat, Matthew P. Muller, Yan Chen, Larissa M. Matukas

    Objective: To evaluate the operational and economic impact of in-house Xpert MTB/RIF Ultra (Ultra) testing for suspected pulmonary tuberculosis (TB) in a low-incidence acute care setting. Design: Prospective implementation study with diagnostic performance assessment and modeled airborne-isolation cost analysis. Setting: Toronto hospital network comprising two acute care hospitals and an outpatient TB clinic. Participants: Adults evaluated for suspected pulmonary TB. Methods: Sputum specimens underwent in-house Ultra testing and reference-laboratory acid-fast bacilli (AFB) smear microscopy and culture. Diagnostic performance was assessed against culture using single-sputum and two-sputum strategies with exact 95% confidence intervals (CIs). Isolation costs were modeled using paired turnaround-time differences and probabilistic sensitivity analysis. Results: Among 164 specimens from 108 patients, median turnaround time was 7 hours for Ultra versus 81 hours for smear (P < .0001); the mean paired reduction was 58.3 hours (SD, 32.2). Compared to mycobacterial culture, single-sputum sensitivity was 73.3% (95% CI, 44.9%–92.2%) for Ultra and 62.5% (24.5%–91.5%) for smear; specificity was 97.8% (92.4%–99.7%) and 92.0% (84.8%–96.5%), respectively. Two-sputum sensitivity was 100.0% for Ultra (3/3; 95% CI, 29.2%–100.0%) and smear (2/2; 15.8%–100.0%); specificity was 100.0% (88.4%–100.0%) and 96.8% (83.3%–99.9%), respectively. Mean modeled savings were CAD $1,277 per patient; 98.7% of simulations favored Ultra. Conclusions: In-house Ultra shortened diagnostic turnaround time and was associated with lower modeled isolation costs, supporting further evaluation of Ultra-informed isolation protocols. Ultra showed favorable diagnostic performance estimates, although results were imprecise.

  • Open Access

    Efficacy of swish and gargle and other collection methods with the use of Abbott ID NOW in COVID-19 detection

    by Amin Motamed Ektesabi, Greg J. German, Le Luu, Claudia dos Santos, Larissa M. Matukas

    Background: To evaluate the efficacy of the Abbott ID NOW system in detecting COVID-19 using different specimen collection methods, emphasizing diagnostic accuracy and patient comfort. Methods: Three cohorts were analyzed, including two using the nasopharyngeal (NP) swab technique and one utilizing the swish-and-gargle (SG) method. Positive percent agreement (PPA), negative percent agreement (NPA), and cycle threshold (Ct) values were assessed to determine the system’s performance. Results: The PPA for the NP swab cohorts averaged around 70%, while the SG cohort exhibited a higher PPA of 80%. All cohorts maintained high NPAs, close to 100%. The SG method significantly reduced false negatives, especially at lower Ct values, indicative of elevated levels of viral RNA. Additionally, the NP swab method, often uncomfortable, posed challenges in repeated testing scenarios, particularly among healthcare workers. Conclusion: While the Abbott ID NOW system demonstrates reliable COVID-19 detection, the SG method emerges as a superior collection technique to NP swabs, offering enhanced diagnostic accuracy and improved comfort for test takers. This study underscores the importance of selecting appropriate collection methods to ensure accurate and efficient COVID-19 testing.

  • Open Access

    A Brief Review of MicroRNA Profiling in Human Prostate Cancer Tissues and Plasma

    by Georgios Kallinikas, Amin M. Ektesabi, Chirag M. Vaswani, Georgios Haronis, Eirini Kallinika, Diomidis Kozyrakis, Evangelos Rodinos, Athanasios Filios, Panagiotis Filios, Despoina Mityliniou, et al.

    (1) Background: The gold standard, prostate-specific antigen (PSA) screening lacks the sensitivity and specificity required for confident, early prostate-cancer detection. MicroRNAs (miRNAs) are small, highly stable, non-coding RNAs whose expression changes reproducibly in malignancy and therefore offer promise as minimally invasive biomarkers. Although prostate cancer biopsies are the gold standard for prostate cancer diagnosis, limitations in the field continue to persist. Since circulating fluids can also be a source of miRNA biomarkers, we investigated the overlap between miRNAs enriched in prostate cancer tissue and those isolated from the plasma of patients with prostate cancer. (2) Methods: We synthesized the published literature (PubMed, Google Scholar, ResearchGate, 2005–April 2025) and re-analyzed three Gene Expression Omnibus (GEO) datasets (GSE54516, GSE21032—tissue; GSE206793—plasma) to identify miRNAs consistently dysregulated in prostate cancer tissue and circulation. (3) Results: Of the 318 screened full-text articles, 24 met the inclusion criteria. From the GEO reanalysis (false-discovery-rate < 0.05, |log2FC| ≥ 1), 219 and 326 miRNAs were differentially expressed in tissue, whereas 12 were altered in plasma. Two miRNAs—miR-449b and miR-455-3p—were common in both compartments, highlighting their translational potential as liquid biopsy surrogates of tumor biology. (4) Conclusions: We summarize functional evidence for leading tumor-suppressive (e.g., miR-205, miR-23b, miR-455-3p) and oncogenic (e.g., miR-21, miR-182, miR-449b) candidates, discuss their intersection with the androgen-receptor, TGF-β, WNT/β-catenin, and PI3K-AKT signaling, and outline outstanding requirements for the clinical qualification of miRNA panels in prostate cancer.


  • Open Access

    Caspase-8: Arbitrating Life and Death in the Innate Immune System

    by Sahil Gupta, Monica Aida Lopez, Amin M. Ektesabi, James N. Tsoporis, Chirag M. Vaswani, Shil Y. Gandhi, Gregory D. Fairn, Claudia C. Dos Santos, John C. Marshall

    The canonical function of caspase-8 is to control timely cellular apoptosis to maintain tissue homeostasis and clear dysfunctional cells; however, emerging findings reveal novel, non-canonical roles of caspase in addition to regulating cellular apoptosis, including inflammatory response regulation, immune function, and cell differentiation. Furthermore, the functional versatility of caspase-8 is reported to be contingent on the presence and dimerization of various isoforms, which are produced through alternative splicing, altering its function and protein–protein interactions. Equally important are post-translational modifications, including phosphorylation and ubiquitination, which can act as a nexus to control caspase-8 activity and cellular localization. Here, we review the alternative splicing and post-translational modifications made to caspase-8 and discuss their influence on its canonical and non-canonical roles.


  • Open Access

    A Brief Overview of Cholinergic and Phosphodiesterase-5 Inhibitors in Diabetic Bladder Dysfunction

    by Georgios Kallinikas, Georgios Haronis, Eirini Kallinika, Diomidis Kozyrakis, Evangelos Rodinos, Athanasios Filios, Panagiotis Filios, Despoina Mityliniou, Konstantinos Safioleas, Anastasios Zarkadas, et al.

    Diabetic bladder dysfunction (DBD) comprises a wide spectrum of lower urinary tract symptoms that impact diabetic patients’ lives, including urinary frequency, urgency, incontinence, and incomplete bladder emptying. To relieve symptoms, anticholinergics have been widely prescribed and are considered an effective treatment. There is increasing evidence that diabetic patients may benefit from the use of phosphodiesterase 5 (PDE5) inhibitors. This narrative review aims to provide a brief overview of the pathophysiology of DBD along with a focus on cholinergic and phosphodiesterase inhibitors as therapies that benefit DBD. An examination of the literature suggests compelling avenues of research and underscores critical gaps in understanding the mechanisms underlying DBD. New tools and models, especially rodent models, are required to further elucidate the mechanisms of action of current therapies in the treatment of DBS.


  • Open Access

    Tiny Guides, Big Impact: Focus on the Opportunities and Challenges of miR-Based Treatments for ARDS

    by Chirag M. Vaswani, Julia Simone, Jacqueline L. Pavelick, Xiao Wu, Greaton W. Tan, Amin M. Ektesabi, Sahil Gupta, James N. Tsoporis, Claudia C. dos Santos

    Acute Respiratory Distress Syndrome (ARDS) is characterized by lung inflammation and increased membrane permeability, which represents the leading cause of mortality in ICUs. Mechanical ventilation strategies are at the forefront of supportive approaches for ARDS. Recently, an increasing understanding of RNA biology, function, and regulation, as well as the success of RNA vaccines, has spurred enthusiasm for the emergence of novel RNA-based therapeutics. The most common types of RNA seen in development are silencing (si)RNAs, antisense oligonucleotide therapy (ASO), and messenger (m)RNAs that collectively account for 80% of the RNA therapeutics pipeline. These three RNA platforms are the most mature, with approved products and demonstrated commercial success. Most recently, miRNAs have emerged as pivotal regulators of gene expression. Their dysregulation in various clinical conditions offers insights into ARDS pathogenesis and offers the innovative possibility of using microRNAs as targeted therapy. This review synthesizes the current state of the literature to contextualize the therapeutic potential of miRNA modulation. It considers the potential for miR-based therapeutics as a nuanced approach that incorporates the complexity of ARDS pathophysiology and the multifaceted nature of miRNA interactions.


  • Open Access

    Pre-Clinical Studies of MicroRNA-Based Therapies for Sepsis: A Scoping Review

    by Amin M. Ektesabi, Julia Simone, Chirag Vaswani, Greaton W. Tan, Yanbo Wang, Jacqueline L. Pavelick, Xiao Wu, Janice Tai, Sahil Gupta, James N. Tsoporis, et al.

    Background: Sepsis is a severe and life-threatening condition triggered by a dysregulated response to infection, leading to organ failure and, often, death. The syndrome is expensive to treat, with survivors frequently experiencing reduced quality of life and enduring various long-term disabilities. The increasing understanding of RNA, RNA biology, and therapeutic potential offers an unprecedented opportunity to develop innovative therapy. Objective: This study is a scoping review focusing on pre-clinical studies of microRNA (miRNA)-based therapies for sepsis. Methodology: A scoping review. The search strategy identified papers published in PubMed until 15 October 2023, using the keywords (microRNA) AND (sepsis) AND (animal model). Inclusion criteria included papers that used either gain- or loss-of-function approaches, excluding papers that did not focus on microRNAs as therapy targets, did not include animal models, did not show organ failure-specific assessments, and focused on microRNAs as biomarkers. The PRISMA-ScR guideline was used in this study. Results: A total of 199 articles were identified that featured the terms “microRNA/miRNA/miR”, “Sepsis”, and “animal model”. Of these, 51 articles (25.6%) employed miRNA-based therapeutic interventions in animal models of sepsis. Of these, 15 studies extended their inquiry to include or reference human clinical data. Key microRNAs of interest and their putative mechanisms of action in sepsis are highlighted. Conclusions: The body of work examined herein predominantly addresses various dimensions of sepsis-induced organ dysfunction, supporting the emerging role of miRNAs as potential therapeutic candidates. However, nearly 5% of papers on miR-based therapy have been retracted over the past 5 years, raising important concerns regarding the quality and complexity of the biology and models for assessing therapeutic potential.

  • Open Access

    DJ-1 Deficiency Protects against Sepsis-Induced Myocardial Depression

    by James N. Tsoporis, Hajera Amatullah, Sahil Gupta, Shehla Izhar, Amin M. Ektesabi, Chirag M. Vaswani, Jean-Francois Desjardins, Golam Kabir, Ana Paula Teixera Monteiro, Amir K. Varkouhi, et al.

    Oxidative stress is considered one of the early underlying contributors of sepsis-induced myocardial depression. DJ-1, also known as PARK7, has a well-established role as an antioxidant. We have previously shown, in a clinically relevant model of polymicrobial sepsis, DJ-1 deficiency improved survival and bacterial clearance by decreasing ROS production. In the present study, we investigated the role of DJ-1 in sepsis-induced myocardial depression. Here we compared wildtype (WT) with DJ-1 deficient mice at 24 and 48 h after cecal ligation and puncture (CLP). In WT mice, DJ-1 was increased in the myocardium post-CLP. DJ-1 deficient mice, despite enhanced inflammatory and oxidative responses, had an attenuated hypertrophic phenotype, less apoptosis, improved mitochondrial function, and autophagy, that was associated with preservation of myocardial function and improved survival compared to WT mice post-CLP. Collectively, these results identify DJ-1 as a regulator of myocardial function and as such, makes it an attractive therapeutic target in the treatment of early sepsis-induced myocardial depression.


  • The Trojan, miR193b-5p, in Virus-Induced Acute Respiratory Distress Syndrome (ARDS)

    by C.M. Vaswani, A.K. Varkouhi, A.P. Teixeira, A. Ektesabi, M. Kim, P. Plant, T. Watts, T. Moraes, V. Capelozzi, F.F. Cruz, et al.